A major trial of a promising gene therapy for Duchenne muscular dystrophy has fallen short, but researchers say the lessons learned could pave the way for better, more effective treatments.
Categories
Recent Posts
- What’s Ahead for Your 2026 National Ambassador
- A caregiver’s birthday offers an opportunity to practice self-care
- Solid Biosciences Shares Update on INSPIRE DUCHENNE Trial Evaluating SGT-003
- Avidity Biosciences Managed Access Program (MAP) – Frequently Asked Questions
- New ‘pothole-filling’ RNA strategy targets the genetic root of DM1
Archive
- January 2026
- December 2025
- November 2025
- October 2025
- September 2025
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
